5,999 Shares in Charles River Laboratories International, Inc. $CRL Acquired by Quantitative Investment Management LLC

Quantitative Investment Management LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 5,999 shares of the medical research company’s stock, valued at approximately $1,360,000.

Several other institutional investors also recently made changes to their positions in the stock. Invesco Ltd. increased its position in Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after purchasing an additional 1,446,972 shares in the last quarter. Victory Capital Management Inc. lifted its position in Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock valued at $137,935,000 after buying an additional 684,586 shares in the last quarter. Ameriprise Financial Inc. lifted its position in Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock valued at $96,005,000 after buying an additional 575,039 shares in the last quarter. Amundi grew its stake in Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock worth $133,397,000 after buying an additional 492,301 shares during the period. Finally, Norges Bank purchased a new stake in Charles River Laboratories International during the fourth quarter worth approximately $96,765,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on CRL. Barclays reissued an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. TD Cowen upped their price target on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Piper Sandler set a $300.00 price target on Charles River Laboratories International in a report on Monday, August 10th. Robert W. Baird set a $291.00 price objective on Charles River Laboratories International in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $255.65.

Insider Buying and Selling

In other news, EVP Victoria L. Creamer sold 4,179 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president directly owned 30,051 shares in the company, valued at approximately $7,788,017.16. This represents a 12.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Birgit Girshick sold 6,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total transaction of $1,819,350.00. Following the sale, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at $10,080,038.70. The trade was a 15.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 165,990 shares of company stock worth $42,606,388 over the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $289.02 on Tuesday. The firm has a 50-day moving average of $248.22 and a two-hundred day moving average of $198.15. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The stock has a market cap of $13.80 billion, a P/E ratio of -59.59, a PEG ratio of 3.03 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $303.30.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.